Understand the source comparison
FST-344: Research Applications Comparison
Before diving into specific scenarios, here's how FST-344 compares to other myostatin-targeting interventions in research settings. This table summarizes mechanism, distribution, documented effects, and current research status. FST-344 (systemic injection) Myo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before diving into specific scenarios, here's how FST-344 compares to other myostatin-targeting interventions in research settings. This table summarizes mechanism, distribution, documented effects, and current research status.
- FST-344 (systemic injection)
- Myostatin and activin binding; prevents receptor activation
- Systemic circulation; reaches multiple organs
- 18–35% muscle mass increase in rodents; 12–24% glucose improvement in metabolic models
- Preclinical only; no published human trials
- Best candidate for systemic muscle wasting applications; off-target activin binding may complicate safety profiling
- FST-315 (local injection)
- Myostatin and activin binding; cell-surface localization
- Localized to injection site or expression site
- 30–41% localized muscle hypertrophy; minimal systemic effect
- Preclinical only; gene therapy tested in phase I for FSHD
- Preferred for localized applications (tendon repair, single-muscle targeting); limited utility for whole-body interventions
- Myostatin antibody (e.g., domagrozumab)
- Neutralizing antibody that binds circulating myostatin
- Systemic; long half-life (14–21 days)
- 5–8% lean mass increase in human trials (sarcopenia, cachexia); modest strength gains
- Phase II trials completed; no FDA approval yet
- High specificity for myostatin reduces off-target risk; lower magnitude of effect vs FST-344 in animal comparisons
- ACVR2B decoy receptor
- Soluble receptor that sequesters myostatin and activins before binding endogenous receptors
- Systemic
- 15–25% muscle mass increase in rodents; broad activin inhibition
- Phase I/II in humans; safety concerns around off-target effects (bleeding, telangiectasia)
- Potent but non-selective; inhibits activin A/B systemically, raising cardiovascular and reproductive concerns
- Myostatin propeptide
- Binds mature myostatin to prevent activation; endogenous inhibitor
- Systemic (when administered exogenously)
- 10–15% muscle mass increase; shorter half-life than antibodies
- Preclinical research; minimal human data
- Lower binding affinity than FST-344; requires higher doses or frequent administration
- The bottom line: FST-344 sits between highly specific interventions (myostatin antibodies) and broad-spectrum inhibitors (ACVR2B decoys) in terms of selectivity and potency. It binds myostatin with high affinity but also binds activins, which introduces metabolic and anti-inflammatory effects beyond muscle alone. For researchers studying muscle growth mechanisms, FST-344 offers systemic distribution and multi-tissue effects that localized interventions cannot match. For clinical translation, the lack of human pharmacokinetic data and undefined dosing remain the primary barriers.